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Take home message: Exhaled nitric oxide fraction measured in newborns before exposure to 
environmental factors is not associated with school age asthma development 
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Exhaled nitric oxide fraction (FeNO) is a non-invasive biomarker that is elevated in subjects 
with asthma and allergic diseases [1]. Nitric oxide (NO) is produced by three NO synthase 
(NOS) enzymes: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS), all present in 
the human lung [2]. The increase of FeNO in asthmatic patients has mainly been attributed to 
an activation of iNOS, mediated through proinflammatory cytokines in the airways [3].  
Early monitoring of airway inflammation assessed by elevated FeNO provides information on 
asthma evolvement and helps to identify subjects at risk. Few studies have investigated the 
association between FeNO during early childhood and asthma at school age. In 
preschoolchildren with recurrent respiratory symptoms, those with higher FeNO were at an 
increased risk for asthma at 6 years [4]. In a selected cohort of infants with eczema, increased 
FeNO prior to any wheezing episodes was associated with an increased risk for asthma at 5 
years [5]. Notably, in these studies, FeNO was measured in high-risk children that were 
already exposed to environmental factors known to modify FeNO levels [6-8].  
The value of FeNO after birth as predictive for later symptoms before relevant exposure to 
environmental factors has been prospectively investigated in only two studies [9, 10]. Latzin 
et al. reported that infants born to atopic mothers had increased FeNO prior to respiratory 
symptoms, and that this association was enhanced in mothers who smoked [9]. In infants born 
to asthmatic mothers, Chawes et al. showed that increased FeNO was associated with 
recurrent wheezing episodes during the first year of life, but not thereafter [10].  
Taken together, while there is cumulative evidence that elevated FeNO in high-risk children 
after a possible impact by environmental exposures is associated with later asthma [4, 5], it is 
unknown if FeNO after birth, prior to a possible influence by postnatal environmental 
exposures and first respiratory symptoms is associated with asthma. Given that environmental 
factors are known to induce NOS activity and modify FeNO levels [6, 7, 11, 12], we 
hypothesised that FeNO measured after birth, and before relevant exposure to these factors, is 
not associated with asthma at school age. 
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The aim of this prospective cohort study was to investigate if FeNO levels after birth in 
unselected newborns are associated with asthma or atopy at school age.  
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This prospective birth cohort study comprised of unselected, healthy, term-born infants 
recruited in the region of Bern, Switzerland [13]. At 5 weeks of age, FeNO from multiple 
breaths during natural sleep was measured, as previously described [9, 14], with a rapid 
response chemiluminescence analyser (CLD 77; EcoMedics, Duernten, Switzerland; Analysis 
software: WBreath version 3.28.0.0, ndd, Zurich, Switzerland).  
At 6 years, asthma was assessed by study physicians with questions adapted from the 
International Study of Asthma and Allergies in Childhood (ISAAC) [15], defined as a history 
of wheezing within the 12 months prior to follow-up. Study physicians assessed atopy, 
defined as allergic asthma, allergic rhinitis, atopic dermatitis or positive skin prick test (SPT). 
An SPT, including 7 common allergens, was determined positive in the case of hives bigger 
than positive control histamine in any of the tested allergens [13]. We assessed risk factors for 
asthma or atopy of the child: parental asthma was defined as self-reported or doctor-
diagnosed asthma; parental atopic disease was defined as allergic asthma, hay fever, or 
eczema by history. 
The Governmental Ethics Committee of the Canton of Bern, Switzerland approved the study 
and informed written consent was obtained at enrolment. 
Logistic regression was used for analysis of an association between FeNO at birth and 
asthma, atopy and positive SPT at school age. Adjustment for confounders (e.g. parental 
asthma and atopy) and nonconfounding factors (minute ventilation, known to modify FeNO 
levels [16]) was done. Linear regression was used for the analysis of an association between 
parental variables and FeNO at birth. Results were reported as odds ratio (OR) or difference 
in FeNO (ppb) with 95% confidence intervals (95% CI). Data were analysed with STATA® 
13 (STATA Corporation, College Station TX). Patient characteristics for those with and 
without follow-up were compared using Mann-Whitney U and Chi-squared tests.  
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We measured FeNO in n=278 infants with n=44 (16%) being excluded for technical reasons, 
resulting in n=234 subjects. Of those n=26 (12%) were lost to follow-up, resulting in n=208 
final study participants. Demographics, exposure to risk factors and FeNO levels did not 
differ between subjects followed-up and those lost to follow-up (data not shown). For the 
entire group, neither maternal atopy, nor maternal smoking was associated with postnatal 
FeNO.  Smoking during pregnancy was only associated with decreased FeNO levels in infants 
of non-atopic mothers (-2.91 ppb, 95% CI -5.76 – -0.048). These findings were similar to 
previously published data [16], although the fraction of smoking mothers was lower in this 
study (9% versus 13% in [16]). At 5 weeks, mean FeNO was 13.9 ppb, (range 1.8–32.9 ppb). 
Parents of n=43 (20%) had asthma and n=126 (61%) were atopic; n=19 (10%) mothers 
smoked during pregnancy. Among 6-year olds (range 5–7 years), n=31 (15%) had asthma 
with n=13 (6%) allergic asthma cases, and none of the children used corticosteroids. There 
were n=62 (30%) atopics, and in n=164 an SPT was completed with n=26 (19%) being 
positive.  
FeNO at birth was not associated with asthma, atopy, or positive SPT at school age. Per one 
ppb increase in FeNO, the simple and adjusted OR (95% CI) for asthma were 0.99 (95% CI 
0.92–1.07) and 0.97 (95% CI 0.89–1.06); for atopy 0.99 (95% CI 0.94–1.05) and 0.99 (95% 
CI 0.94–1.06); and for positive SPT 0.95 (95% CI 0.88–1.03) and 0.95 (95% CI 0.87–1.03) 
(table 1), respectively. 
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Our study is the first to investigate the association between FeNO at birth and asthma at 
school age in unselected infants. It was previously shown that the association of elevated 
FeNO after birth with respiratory symptoms is restricted to infancy [10]. In this study, we 
found supporting evidence for this finding since FeNO after birth was not associated with 
diagnosis of school age asthma. 
Based on this finding, and on previous studies in selected high-risk populations, we propose 
two different models on FeNO metabolism in early infancy (figure 1): 
Model 1: Elevated FeNO is an expression of an intrinsic mechanism, determined by pre-and 
early postnatal risk factors. In this model, FeNO levels during infancy would then not be 
altered by environmental factors, and FeNO measured at birth could serve as a predictor for 
later asthma and atopy. 
Model 2: Environmental factors (e.g. infections, air pollution) are needed to induce iNOS [6, 
7, 11] which then results in elevated FeNO. In this hypothesis, we would expect no 
association between FeNO at birth (measured before environmental exposures) and school 
age outcomes. FeNO may then only serve as a phenotype specific biomarker in infants after 
the first activation of the environmentally or genetically induced iNOS.  
We speculate that the second, rather than the first, model better explains NO metabolism after 
birth, since studies measuring FeNO after environmental exposures found an association 
between FeNO with asthma development, while our study, measuring FeNO before 
environmental exposures, did not find any association.  
Measurements were performed using a face mask, which is the only available technique for 
measuring FeNO in infants at this time. This introduces the possibility that FeNO from the 
upper airways contributes to the overall FeNO measured. However, we believe this potential 
contribution is unlikely due to the fact that the nasal sinuses of infants are not developed.  
Asthma prediction with FeNO might further be hampered by the physiological variability of 
FeNO levels per se, by the intersubject variability of up to 50% [17], and influenced by 
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different measurement techniques. In school-aged children, comparison of FeNO measured 
from single versus multiple breaths resulted in higher FeNO values using the latter technique 
[18]. Multiple-breath FeNO measurement technique is, at this time, the only one available for 
infants. The present study is limited by the low number of asthmatics (n=31) and the 
questionnaire-based assessment for diagnosis, which could lead to possible misclassification. 
In general, the cohort reflects the epidemiological situation in Switzerland, with a low 
prevalence of mild to moderate asthmatics. Coincidentally, however, in our study sample only 
mild intermittent asthmatics (without corticosteroid use in the last 12 months) were included. 
However, this study was conducted in a prospective unselected cohort, representing the 
general population. In contrast to previous studies in high-risk populations, we measured 
FeNO at a single point in time after birth, excluding possible age- or time dependent effects 
on FeNO levels. 
The interpretation of FeNO levels, its predictive value and its modifiers, are age dependent [4, 
5, 7, 9-11]. Postnatal FeNO metabolism seems to be modified by various environmental 
factors. On a cellular level, maternal tobacco smoke modified NOS activity in fetal vascular 
bed in newborns [12]. Consistent with this observation, postnatal FeNO is modified by 
prenatal tobacco smoke exposure in offspring [16, 17], interestingly enough, in an interaction 
with maternal atopy [16].  In contrast to the pre- and early postnatal situation, infancy and 
preschool age seems to be critical for further gene-environment interactions through 
exposures other than smoking and maternal atopy and their impact upon NO metabolism [4, 
5].  
In summary, we show that postnatal FeNO measured in unselected healthy newborns is not 
associated with asthma diagnosis at school age. We speculate that NO metabolism may play a 
role in the pathophysiology of childhood asthma and atopy only after exposure to 
environmental factors at preschool age. To confirm that environmental exposures indeed 
modify NOS expression during infancy, frequent longitudinal assessment of FeNO levels and 
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NOS expression would be necessary. Our findings should encourage further research on 
factors impacting upon NO metabolism during infancy that can serve as targets for new 
preventive strategies on childhood asthma development.  
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TABLE 1  Association between exhaled nitric oxide in newborns and subsequent diagnoses 
of asthma, atopy and positive prick test in school-aged children 
  
Exposure fraction of exhaled nitric oxide 
 
Simple§ model 
  
Adjusted£ model 
 
Outcome 
 
OR 
 
(95% CI) 
 
p-value 
  
OR 
 
(95% CI) 
 
p-value 
        
Asthma+ 0.99 (0.92–1.07) 0.970  0.97 (0.89–1.06) 0.586 
Atopy$ 0.99 (0.94–1.05) 0.976  0.99 (0.94–1.06) 0.971 
Prick positive#  0.95 (0.88–1.03) 0.285  0.95 (0.87–1.03) 0.256 
Odds ratios (OR) and 95% confidence intervals (CI) per one ppb increase in exhaled nitric 
oxide fraction (FeNO) were determined by logistic regression. +: defined as a history of 
wheezing within the 12 months prior to follow-up. $: defined if one of the following was 
present: asthma, allergic rhinitis, atopic eczema and positive prick test. #: positive in case of 
hives bigger than positive control histamine in any of the tested allergens. §: FeNO was 
adjusted for minute ventilation [16]. £: This model was additionally adjusted for sex, parental 
asthma, parental atopy and smoking during pregnancy.  
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FIGURE 1 We measured fractional exhaled nitric oxide (FeNO) at 5 weeks of age, while 
previous studies measured FeNO in older children during time ranges. Based on this and 
previous studies, we propose two hypotheses on FeNO metabolism during infancy: 
Model 1 (dashed line): Elevated FeNO is an expression of an intrinsic mechanism, determined 
by pre-and early postnatal risk factors. In this model, FeNO levels during the first year of life 
would then not be altered by environmental factors, and FeNO measured at birth could serve 
as a predictor for asthma/atopy at school age.  
Model 2 (continuous line): Environmental factors (e.g. infections, air pollution) are needed to 
induce nitric oxide synthases (NOS) which then results in elevated FeNO. In this model, we 
would expect no association between FeNO at birth (measured before environmental 
exposures) and asthma/atopy at school age. FeNO may then only serve as a phenotype 
specific biomarker in infants after the first activation of environmentally induced NOS.   
 
